Table 1.
Summary of the Correlation of Platelet Count with Tumor
| Disease Model/Patient Type | Comments | Ref. |
|---|---|---|
| Hepatocellular carcinoma (HCC) | Platelet count may be a potential biomarker for predicting the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma treated with catheter arterial chemoembolization. | Wang B et al,15 |
| HCC | Platelet count was better than indocyanine green (ICG) R15 level in predicting the occurrence of liver failure (PHLF) in patients with HCC with preserved liver function. | Tomimaru Y et al,20 |
| HCC | Decreased platelet cell count and higher MPV are associated with better prognosis in patients with advanced HCC. | Scheiner B et al,21 |
| Liver cancer | Decrease in the number of platelets indicates a poor prognosis for patients with liver cirrhosis and liver cancer, while an increase in platelet count indicates a poor prognosis for patients without cirrhosis. | Midorikawa Y et al,19 |
| Gastric cancer | Platelet count may be a cost-effective biomarker for screening and monitoring poor prognosis of gastric cancer patients who have undergone radical surgery. | Oh SE et al,16 |
| Lung cancer | Increased platelet count and decreased MPV were the poor prognosis of lung cancer patients, and platelet count was also associated with bone, soft tissue, lymph node metastasis and malignant pleural effusion. | Ohuchi M et al,22 |
| Lung adenocarcinoma (ADC) | Even if the platelet count is within the reference range, elevated platelet counts were significantly associated with high lymph node metastasis rates in patients with ADC. | Qu CH et al,23 |
| Non-small cell lung cancer (NSCLC) | Platelet count could predict the prognosis of patients with NSCLC treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). | Xu L et al,24 |
| Cervical cancer | The combination of platelet count and International Federation of Obstetrics and Gynecology (FIGO) staging improves the predictive performance of FIGO staging and provides additional risk stratification for patients with operable cervical cancer. | Zheng RR et al,17 |
| Head and neck squamous cell carcinoma (HNSCC) | Univariate analysis showed that platelet count was significantly correlated with the survival rate of patients with HNSCC. However, in multivariate analysis, platelet count lost its prognostic ability. | Pardo L et al,25 |
| Colorectal cancer (CRC) | MPV/platelet count may be helpful in the diagnosis of CRC. | Wu YY et al,26 |
| CRC | Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) may be useful markers for the diagnosis and early recognition of different stages of CRC. | Stojkovic Lalosevic M et al,27 |
| CRC | High platelet counts were associated with systemic inflammation of CRC. However, this study was unable to prove a statistically significant correlation between platelet count, aspirin use and tumor infiltrating immune cell density. | Väyrynen JP et al,18 |
| Rectal cancer | The mortality of rectal cancer patients with high platelet counts before surgery is higher than that of rectal cancer patients with low platelet levels. Research results suggest that preoperative platelet count can be used as an important indicator for predicting the prognosis of rectal cancer, but its prognostic value for colon cancer needs to be further clarified. | Chen LL et al,28 |
| Rectal cancer | In locally advanced rectal cancer, elevated platelet count before neoadjuvant radiotherapy and chemotherapy is a sign of poor prognosis. | Belluco C et al,29 |
| Ovarian cancer | In multivariate analysis, age, CA125 and thrombocytosis independently predicted the presence of ovarian malignancies. | Watrowski R et al,30 |
| Ovarian cancer | Mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR) and platelet count in the detection of malignant ovarian tumors have been evaluated as useful new markers. | Yilmaz E et al,31 |
| Epithelial ovarian cancer (EOC) | Platelet count can be used as a biomarker to monitor EOC recurrence and predict treatment response. | Hu Q et al,32 |
| Prostate cancer | The results of the study indicate that performance status (PS) and platelet count are independent prognostic factors for evaluating disease-specific survival (DSS) in patients with metastatic prostate cancer receiving endocrine therapy. | Shimodaira K et al,33 |
| Diffuse large B-cell lymphoma (DLBCL) | Platelet count and albumin level are useful prognostic factors, and their combined use can even predict the survival of elderly patients with DLBCL. | Ochi Y et al,34 |
| Acute myeloid leukemia (AML) | Platelet count can predict the survival rate of patients with moderate-risk AML. | Zhang Y et al,35 |
| AML | The platelet count before treatment has predictive value for the prognosis of patients with non-M3 AML. | Zhang Q et al,36 |
| Breast cancer | Platelets have important predictive value for the prognosis of patients with ipsilateral supraclavicular lymph node metastasis (ISLN) in breast cancer patients, indicating that platelet counts can be used to distinguish high-risk patients and thus obtain clinical benefits. | Liu S et al,37 |
| T-cell lymphoma | The results of the study prove that the decrease in the number of platelets is an independent prognostic factor for the survival of patients with peripheral T-cell lymphoma. | Choi M et al,38 |